COVERA-HS Drug Patent Profile
✉ Email this page to a colleague
When do Covera-hs patents expire, and when can generic versions of Covera-hs launch?
Covera-hs is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in COVERA-HS is verapamil hydrochloride. There is one drug master file entry for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Covera-hs
A generic version of COVERA-HS was approved as verapamil hydrochloride by EXELA PHARMA on March 30th, 1984.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for COVERA-HS?
- What are the global sales for COVERA-HS?
- What is Average Wholesale Price for COVERA-HS?
Summary for COVERA-HS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 78 |
| Clinical Trials: | 4 |
| DailyMed Link: | COVERA-HS at DailyMed |
Recent Clinical Trials for COVERA-HS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Assiut University | Early Phase 1 |
| Beverly S. Wical, M.D. | Phase 2 |
| Ann & Robert H Lurie Children's Hospital of Chicago | Phase 2 |
US Patents and Regulatory Information for COVERA-HS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-001 | Feb 26, 1996 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-002 | Feb 26, 1996 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for COVERA-HS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-002 | Feb 26, 1996 | ⤷ Start Trial | ⤷ Start Trial |
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-002 | Feb 26, 1996 | ⤷ Start Trial | ⤷ Start Trial |
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-001 | Feb 26, 1996 | ⤷ Start Trial | ⤷ Start Trial |
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-001 | Feb 26, 1996 | ⤷ Start Trial | ⤷ Start Trial |
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-002 | Feb 26, 1996 | ⤷ Start Trial | ⤷ Start Trial |
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-002 | Feb 26, 1996 | ⤷ Start Trial | ⤷ Start Trial |
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-002 | Feb 26, 1996 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for COVERA-HS
See the table below for patents covering COVERA-HS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 15606 | ⤷ Start Trial | |
| Germany | 3172338 | ⤷ Start Trial | |
| European Patent Office | 0052917 | OSMOTIC DEVICE WITH HYDROGEL DRIVING MEMBER | ⤷ Start Trial |
| Japan | S5793065 | PERMEATION APPARATUS HAVING HYDROGEL DRIVE MEMBER | ⤷ Start Trial |
| Japan | S6043045 | ⤷ Start Trial | |
| Mexico | 174160 | DISPOSITIVO OSMOTICO CON UN MIEMBRO IMPULSOR DE HIDROGEL | ⤷ Start Trial |
| Mexico | 9203553 | DISPOSITIVO OSMOTICO CON UN MIEMBRO IMPULSOR DE HIDROGEL. | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch